Pharmaceutical intelligence for ZENOCUTUZUMAB-ZBCO with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

RegulatoryAugust 6, 2026

FDA grants priority review for BLA761352 (ZENOCUTUZUMAB-ZBCO) by Merus N.V.

The FDA has granted priority review status for the supplemental biologics application BLA761352 for ZENOCUTUZUMAB-ZBCO.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryAugust 6, 2026

FDA grants priority review for BLA761352 (ZENOCUTUZUMAB-ZBCO) by Merus N.V.

The FDA has granted priority review status for the supplemental biologics application BLA761352 for ZENOCUTUZUMAB-ZBCO.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

FDA →

Therapeutic areas

Monoclonal Antibody →

Oncology →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.